Comparison of HIV Risk Behaviors Between Clinical Trials and Observational Cohorts in Uganda
Open Access
- 10 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in AIDS and Behavior
- Vol. 24 (10), 2872-2884
- https://doi.org/10.1007/s10461-020-02838-w
Abstract
Many key populations have high-risk behaviors for HIV infection making them suitable for HIV vaccine efficacy trials. However, these behaviors may change when participants enroll into a trial. We used HIV simulated vaccine efficacy trials (SiVETs) nested within observational cohorts of fisherfolks and female sex workers in Uganda to evaluate this difference. We screened observational cohort participants for enrolment into SiVETs, until 572 were enrolled. Those not enrolled (n = 953) continued participation in the observational cohorts. We determined risk behaviors at baseline and at 1 year, assigned a numeric score to each behavior and defined composite score as the sum of reported behaviors. We compared changes in scores over 12 months. Both observational cohorts and SiVETs saw a significant decrease in score but greatest in the SiVETs. Investigators recruiting for trials from these populations should consider the likely effect of reduction in risk behaviors on incident HIV infection and trial statistical power.Keywords
This publication has 36 references indexed in Scilit:
- HIV Risk-Reduction Counseling and Testing on Behavior Change of MSMPLOS ONE, 2013
- HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, UgandaSexually Transmitted Infections, 2011
- Prevalence and Incidence of HIV in a Rural Community-Based HIV Vaccine Preparedness Cohort in Masaka, UgandaPLOS ONE, 2011
- Weighing the gold in the gold standard: challenges in HIV prevention researchAIDS, 2010
- Social Influence and Individual Risk Factors of HIV Unsafe Sex among Female Entertainment Workers in ChinaAIDS Education and Prevention, 2010
- SAVVY Vaginal Gel (C31G) for Prevention of HIV Infection: A Randomized Controlled Trial in NigeriaPLOS ONE, 2008
- SAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in GhanaPLOS ONE, 2007
- Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled TrialPLoS Clinical Trials, 2007
- Evidence of a Healthy Volunteer Effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialAmerican Journal of Epidemiology, 2007
- Gender, Work, and HIV Risk: Determinants of Risky Sexual Behavior Among Female Entertainment Workers in ChinaAIDS Education and Prevention, 2006